Alcon, Inc. 是一間眼科護理公司,為全球眼科護理專業人員及其患者研究、開發、製造、分銷及銷售眼科護理產品。公司總部位於瑞士日內瓦。
財務指標
營業收入
2026-06-30
$2.82B
2026-03-31
$2.65B
2025-12-31
$2.71B
2025-09-30
$2.61B
營業支出
2026-06-30
$1.66B
2026-03-31
$1.08B
2025-12-31
$1.16B
2025-09-30
$1.12B
淨利潤
2026-06-30
$0
2026-03-31
$185.32M
2025-12-31
$217M
2025-09-30
$237M
淨利潤率
2026-06-30
0%
2026-03-31
6.98%
2025-12-31
7.98%
2025-09-30
9.06%
每股收益
2026-06-30
$0.84
2026-03-31
$0.85
2025-12-31
$0.78
2025-09-30
$0.79
息稅折舊攤銷前利潤
2026-06-30
$800M
2026-03-31
$564.81M
2025-12-31
$740M
2025-09-30
$664.56M
有效稅率
2026-06-30
100%
2026-03-31
21.25%
2025-12-31
17.8%
2025-09-30
16.25%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$2.82B
$2.65B
$2.71B
$2.61B
營業支出
$1.66B
$1.08B
$1.16B
$1.12B
淨利潤
$0
$185.32M
$217M
$237M
淨利潤率
0%
6.98%
7.98%
9.06%
每股收益
$0.84
$0.85
$0.78
$0.79
息稅折舊攤銷前利潤
$800M
$564.81M
$740M
$664.56M
有效稅率
100%
21.25%
17.8%
16.25%
常見問題
ALC represents Alcon Inc., a global medical company specializing in eye care. Headquartered in Switzerland, Alcon develops, manufactures, and markets products for surgical ophthalmology and vision care. Its portfolio includes intraocular lenses, surgical equipment, and contact lens solutions. The company operates worldwide and is listed on the New York Stock Exchange under the ticker ALC. Alcon was spun off from Novartis in 2019, becoming an independent, publicly traded company focused solely on eye care.
Recent performance for ALC can be tracked through the stock's price chart and percentage changes shown on this page. These figures update regularly to reflect the latest market activity. For the most current performance data, including daily, weekly, and year-to-date moves, refer to the live quote and historical price sections above. Performance may be influenced by factors such as earnings reports, product launches, and broader market conditions affecting the medical device sector.
Evaluating ALC's valuation involves comparing metrics like the price-to-earnings (P/E) ratio, price-to-sales (P/S), and enterprise value-to-EBITDA against peers in the medical device industry. Analysts also consider growth prospects, profitability, and cash flow. Since valuation multiples change with market conditions, check the latest figures on this page. A holistic approach should weigh ALC's competitive position, pipeline, and financial health alongside these metrics.
Yes, ALC stock can be traded outside regular U.S. market hours through pre-market and after-hours sessions, though liquidity is typically lower and spreads may be wider. These extended sessions allow investors to react to news released outside standard trading times. However, not all brokers offer extended-hours trading, and orders may not execute if there is insufficient volume. Check with your brokerage for specific availability and any associated fees or restrictions.
Alcon (ALC) has paid dividends in the past, but dividend policies can change based on company performance and strategic priorities. To confirm whether ALC currently pays a dividend, the amount, and the payment schedule, refer to the dividend section on this page or Alcon's investor relations website. Dividends are not guaranteed and may be suspended or modified at the company's discretion.
Key risks for ALC include regulatory hurdles and product approvals in the medical device sector, competition from other eye care companies, and reliance on successful innovation. Economic downturns may reduce demand for elective surgical procedures, and currency fluctuations can impact international sales. Additionally, litigation, supply chain disruptions, and changes in healthcare reimbursement policies could affect financial results. Investors should review Alcon's risk factors in its annual reports for a comprehensive list.